Health Canada Warns About Fake GLP‑1 Drugs

On Jan 21, 2026 Health Canada issued an advisory warning Canadians against buying or using fake or unauthorized GLP‑1 drugs such as semaglutide—the active ingredient in Ozempic and Wegovy—and tirzepatide‑based Mounjaro and Zepbound. The agency discovered retailers across Canada selling “fauxzempic” both in physical stores and online, and noted that counterfeit products can contain incorrect dosages, harmful contaminants, or be improperly labelled. Health Canada urges consumers to check the eight‑digit Drug Identification Number (DIN) and to obtain prescriptions only from licensed pharmacies. The regulator works with the Canada Border Services Agency to intercept illicit shipments and may seize products or issue warning letters. Users who suspect counterfeit GLP‑1 usage should report side effects to Health Canada and consult a health‑care professional.